Cervical Cancer Market to Experience Novel Combination Therapy Soon

Release Date: 04-Nov-2020

In case of recurrent or metastatic cervical cancer, immune checkpoint inhibitors as well as antibody-drug conjugates have shown promising results. 22% overall response rate was observed in the patients when given new PD-1 checkpoint blocker balstilimab plus the CTLA-4 blocker zalifrelimab, whereas 24% overall response rate was observed in the patients when given investigational antibody-drug conjugate tisotumab vedotin.


In the very first study, a total of 160 patients were enrolled and most of the enrolled patients in the study had received platinum-based chemotherapy before, after this the patients received IV infusions of balstilimab. The end results that were found were: overall response rate 14%. In the next study, 155 patients received balstilimab every two weeks plus zalifrelimab infusions. The observed overall response rate was found to be 22%.  The overall response rate in the patients who received balstilimab monotherapy was 19% and in the combination trial, the overall response rate observed was 27% and 11% respectively. It was concluded by the researchers that the treatment was safe and the drugs used in the study were able to generate an immune response in the patients. It is estimated that the combination of the drugs used in the study could get recognized as novel meaningful therapies for the cancer patients across the globe.

Need custom market research solution? We can help you with that too.